Ascentage Pharma officer files Form 3 report

ASCENTAGE PHARMA GROUP INTERNATIONAL officer Miyara Faical, who serves as Chief Business Officer, has filed an insider ownership report with no trading activity disclosed.

Accepted by SEC EDGAR 06/29/2026 - 03:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL officer Miyara Faical, who serves as Chief Business Officer, has filed an insider ownership report with no trading activity disclosed. All buy, sell, acquire, dispose, exercise, gift, tax-withholding and restructuring counts are zero, indicating no share or derivative transactions in this data set.

Key Figures

Buy shares reported: 0 shares Sell shares reported: 0 shares Derivative exercises: 0 shares +1 more

4 metrics

Buy shares reported 0 shares buyShares in transactionSummary

Sell shares reported 0 shares sellShares in transactionSummary

Derivative exercises 0 shares exerciseShares in transactionSummary

Net buy/sell direction neutral netBuySellDirection in transactionSummary

Key Terms

Chief Business Officer, transactionSummary, derivativeTransactionCount

3 terms

Chief Business Officer financial

"Miyara Faical is listed with officer_title "Chief Business Officer""

A chief business officer (CBO) is the executive responsible for a company's commercial strategy, partnerships, licensing, and business development—essentially the leader who turns technology or products into paying customers and deals. Investors care because the CBO's choices about partnerships, pricing, market entry and revenue models directly influence how fast a company grows and how much future cash flow or value it can deliver; think of the CBO as the company's head coach for winning business and income.

transactionSummary financial

"transactionSummary aggregates buy, sell, acquire, dispose and other counts"

derivativeTransactionCount financial

"derivativeTransactionCount is reported as 0 in transactionSummary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Ascentage Pharma (AAPG) Form 3 filing by Miyara Faical show?

The Form 3 data for Ascentage Pharma’s Chief Business Officer, Miyara Faical, shows no reported share or derivative transactions. All buy, sell, acquire, dispose, exercise, gift, tax-withholding and restructuring counts are recorded as zero in this filing.

Did Ascentage Pharma (AAPG) executive Miyara Faical buy or sell any shares in this Form 3?

No. The transaction summary for Miyara Faical’s Form 3 shows zero buyShares and zero sellShares. It also lists zero acquire and dispose events, indicating no trading activity is captured in this particular insider report.

Are there any option exercises or derivative transactions reported for AAPG’s Chief Business Officer?

No derivative activity is shown. The filing lists exerciseCount and exerciseShares as zero, and derivativeTransactionCount is also zero. This means no options, warrants, or other derivatives are reported as exercised or traded in this data set.

Does the Ascentage Pharma (AAPG) Form 3 include any gifts or tax-withholding share movements?

No. The insider data records giftCount and giftShares as zero, and taxWithholdingCount and taxWithholdingShares are also zero. This indicates there were no share gifts or tax-withholding related share dispositions reported for this officer in the filing.

What restructuring-related share movements are reported for Miyara Faical in AAPG’s Form 3?

The insider summary shows restructuringCount and restructuringShares at zero, meaning no entity restructuring transactions, such as transfers between related entities, are captured for Miyara Faical in this specific Form 3 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Miyara Faical

(Last) (First) (Middle)

C/O ASCENTAGE PHARMA GROUP INC.

700 KING FARM BOULEVARD, SUITE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/25/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This form is filed using a special power of attorney.

No securities are beneficially owned.

	Thomas J. Knapp	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)